PE20030335A1 - Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents
Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidadInfo
- Publication number
- PE20030335A1 PE20030335A1 PE2002000803A PE2002000803A PE20030335A1 PE 20030335 A1 PE20030335 A1 PE 20030335A1 PE 2002000803 A PE2002000803 A PE 2002000803A PE 2002000803 A PE2002000803 A PE 2002000803A PE 20030335 A1 PE20030335 A1 PE 20030335A1
- Authority
- PE
- Peru
- Prior art keywords
- obesity
- systems
- treatment
- indan
- prophylaxia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-OL-SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, 5-TETRAZOLILO, ENTRE OTROS; X ES S, SO, SO2; Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)r-COR6, CH2-CH(NHR7)COR8, FENILO, NAFTILO, BIFENILO, HETEROCICLO, r ES 1-6; R6 Y R8 SON OH, ALQUILO C1-C6, NH2; R7 ES H, CO-ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFONIL-INDAN-1-ONA, 5-CLORO-2-(PROPAN-2-SULFONIL)-INDAN-1-OL, 5-CLORO-2-ETANOSULFONIL-INDAN-1-OL; 5-CLORO-2-METILSULFANIL-INDAN-1-OL. TAMBIEN SE REFIERE AL USO CON CATINAS, FENILPROPANOLAMINAS, AMFEPRAMONAS, MEFENOREX, EFEDRINAS, LEPTINA, DEXANFETAMINAS, ANFETAMINAS, FENFLURAMINAS, ENTRE OTROS. LOS COMPUESTOS TIENEN EFECTO ANOREXICO Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE OBESIDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10142666A DE10142666A1 (de) | 2001-08-31 | 2001-08-31 | Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030335A1 true PE20030335A1 (es) | 2003-05-20 |
Family
ID=7697236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000803A PE20030335A1 (es) | 2001-08-31 | 2002-08-21 | Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20030134879A1 (es) |
| EP (1) | EP1425007B1 (es) |
| JP (1) | JP2005503397A (es) |
| AT (1) | ATE308321T1 (es) |
| AU (1) | AU2002336984B2 (es) |
| CA (1) | CA2458526A1 (es) |
| DE (2) | DE10142666A1 (es) |
| DK (1) | DK1425007T3 (es) |
| ES (1) | ES2250710T3 (es) |
| IL (2) | IL160605A0 (es) |
| MX (1) | MXPA04001852A (es) |
| PE (1) | PE20030335A1 (es) |
| WO (1) | WO2003020263A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10142663B4 (de) | 2001-08-31 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | C2-Disubstituierte Indan-1-ol-Systeme |
| TWI522109B (zh) * | 2009-01-26 | 2016-02-21 | 臺北醫學大學 | 蕨素化合物用於治療糖尿病及肥胖之用途 |
| TWI799691B (zh) * | 2019-03-29 | 2023-04-21 | 景凱生物科技股份有限公司 | 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2345146A1 (fr) * | 1976-03-23 | 1977-10-21 | Logeais Labor Jacques | Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol |
| EP0009554B1 (de) * | 1978-07-27 | 1983-04-27 | Schering Aktiengesellschaft | Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
| AU6548286A (en) * | 1985-10-04 | 1987-04-24 | Maggioni-Winthrop S.P.A. | Fused cycloaliphatic aminoalcohols |
| MX13484A (es) | 1987-10-19 | 1993-05-01 | Pfizer | Procedimiento para la obtencion de tetralinas, cromanos y compuestos relacionados, sustituidos |
| EP0874800B1 (en) * | 1995-12-06 | 2003-08-06 | Venantius Limited | Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity |
| WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| DK0958296T3 (da) | 1996-12-31 | 2003-08-18 | Reddys Lab Ltd Dr | Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme |
| KR20010021936A (ko) | 1997-07-16 | 2001-03-15 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용 |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| EP1078632A1 (en) | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
| DE10142660A1 (de) * | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE10142667B4 (de) * | 2001-08-31 | 2004-06-09 | Aventis Pharma Deutschland Gmbh | C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel |
| DE10142662B4 (de) * | 2001-08-31 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel |
-
2001
- 2001-08-31 DE DE10142666A patent/DE10142666A1/de not_active Withdrawn
-
2002
- 2002-08-17 WO PCT/EP2002/009205 patent/WO2003020263A1/de active IP Right Grant
- 2002-08-17 CA CA002458526A patent/CA2458526A1/en not_active Abandoned
- 2002-08-17 DE DE50204801T patent/DE50204801D1/de not_active Expired - Lifetime
- 2002-08-17 AT AT02772165T patent/ATE308321T1/de active
- 2002-08-17 DK DK02772165T patent/DK1425007T3/da active
- 2002-08-17 JP JP2003524571A patent/JP2005503397A/ja not_active Withdrawn
- 2002-08-17 IL IL16060502A patent/IL160605A0/xx unknown
- 2002-08-17 MX MXPA04001852A patent/MXPA04001852A/es active IP Right Grant
- 2002-08-17 EP EP02772165A patent/EP1425007B1/de not_active Expired - Lifetime
- 2002-08-17 AU AU2002336984A patent/AU2002336984B2/en not_active Ceased
- 2002-08-17 ES ES02772165T patent/ES2250710T3/es not_active Expired - Lifetime
- 2002-08-21 PE PE2002000803A patent/PE20030335A1/es not_active Application Discontinuation
- 2002-08-30 US US10/231,183 patent/US20030134879A1/en not_active Abandoned
-
2004
- 2004-02-26 IL IL160605A patent/IL160605A/en not_active IP Right Cessation
- 2004-12-07 US US11/006,164 patent/US7763662B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2458526A1 (en) | 2003-03-13 |
| ES2250710T3 (es) | 2006-04-16 |
| DK1425007T3 (da) | 2006-03-13 |
| EP1425007B1 (de) | 2005-11-02 |
| US20030134879A1 (en) | 2003-07-17 |
| ATE308321T1 (de) | 2005-11-15 |
| JP2005503397A (ja) | 2005-02-03 |
| DE50204801D1 (de) | 2005-12-08 |
| AU2002336984B2 (en) | 2006-10-26 |
| EP1425007A1 (de) | 2004-06-09 |
| US20050080057A1 (en) | 2005-04-14 |
| DE10142666A1 (de) | 2003-03-20 |
| IL160605A (en) | 2010-12-30 |
| US7763662B2 (en) | 2010-07-27 |
| IL160605A0 (en) | 2004-07-25 |
| WO2003020263A1 (de) | 2003-03-13 |
| MXPA04001852A (es) | 2004-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052739L (no) | CCR5-antagonister som medikamenter | |
| CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
| ATE452129T1 (de) | N-phenyl-2-pyrimidine-amine derivatives | |
| ATE384724T1 (de) | Cyclopropylverbindungen als ccr5 antagonisten | |
| JO2764B1 (en) | Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase | |
| ATE520668T1 (de) | Sigmarezeptor-inhibitoren | |
| DE60323133D1 (de) | Cyclohexylverbindungen als ccr5-antagonisten | |
| NO20081844L (no) | Terapeutiske forbindelser | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
| YU75603A (sh) | Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja | |
| NO20062857L (no) | Farmasoytisk preparat omfattende et sink-hyaluronatkompleks for behandling av multippel sklerose | |
| DK1124841T3 (da) | Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem | |
| MXPA04001847A (es) | Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad. | |
| PT1173176E (pt) | Utilizacao de sistemas policiclicos de 2-amino-tiazole para a preparacao de medicamentos para a profilaxia ou tratamento da obesidade | |
| BR0008519A (pt) | Aplicação de sistemas tiazol policìclicos para apreparação de medicamentos para a profilaxia outratamento da obesidade | |
| PE20030335A1 (es) | Utilizacion de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad | |
| PE20030338A1 (es) | Utilizacion de derivados de sistemas de indan-1-ol-sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad | |
| PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
| CY1106129T1 (el) | Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος | |
| IL160603A0 (en) | C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals | |
| PE20030337A1 (es) | Indan-1-onas sustituidas en c2 y sus derivados, procedimiento para su preparacion y su utilizacion como medicamentos | |
| UY26945A1 (es) | Alcanosulfonatos de fenoxifenilo | |
| MXPA04001853A (es) | Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad. | |
| DOP2001000253A (es) | Alcanosulfonatos de fenoxifenilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |